文献速递中毒与环境急症重症综合管理与镇静镇痛

共暴露于γ-羟基丁酸与甲基苯丙胺神经精神及兴奋效应的减弱相关

Co-exposure to gamma-hydroxybutyrate is associated with attenuated neuropsychiatric and stimulant effects of metamfetamine.
PubMed 文献 · Clin Toxicol (Phila) · 2024-06-17
一句话结论在急诊就诊的甲基苯丙胺中毒患者中,γ-羟基丁酸共暴露与心率、体温及激越发生率显著降低相关。

本研究利用澳大利亚维多利亚州新兴药物网络(EDNAV)前瞻性注册数据,纳入急诊就诊且经血液分析确认暴露于甲基苯丙胺的非法药物使用患者,比较单独甲基苯丙胺、甲基苯丙胺+γ-羟基丁酸、甲基苯丙胺+苯二氮䓬、甲基苯丙胺+γ-羟基丁酸+苯二氮䓬四组的临床与毒理学特征。结果显示,γ-羟基丁酸阳性组甲基苯丙胺血药浓度更高,但就诊时心率、体温和激越发生率显著低于单独甲基苯丙胺组;苯二氮䓬阳性组收缩压显著低于单独甲基苯丙胺组。作者据此提出γ-氨基丁酸B受体激动剂可能有助于急性甲基苯丙胺中毒管理的假设。

要点

  • 甲基苯丙胺+γ-羟基丁酸组(n=153)中位心率72次/分,显著低于单独甲基苯丙胺组(n=81)的110次/分(P<0.0001)。
  • 甲基苯丙胺+γ-羟基丁酸组中位体温35.8°C,显著低于单独甲基苯丙胺组的36.5°C(P<0.0001)。
  • 甲基苯丙胺+γ-羟基丁酸组镇静(GCS<9)发生率63%,显著高于苯二氮䓬组27%(P<0.0001)和单独甲基苯丙胺组15%(P<0.0001)。
  • 甲基苯丙胺+γ-羟基丁酸+苯二氮䓬组激越发生率17%(P<0.0001),甲基苯丙胺+γ-羟基丁酸组34%(P=0.0004),均显著低于单独甲基苯丙胺组的58%。
  • 苯二氮䓬阳性组就诊时收缩压显著低于单独甲基苯丙胺组(P≤0.001)。

适用人群与场景

  • 澳大利亚维多利亚州急诊科就诊的非法药物使用患者,经血液分析确认暴露于甲基苯丙胺。
  • 排除共暴露于其他兴奋剂或镇静剂(除γ-羟基丁酸和苯二氮䓬外)的病例。

诊断标准与关键阈值

  • 分组依据为血液分析确认的暴露:单独甲基苯丙胺、甲基苯丙胺+γ-羟基丁酸、甲基苯丙胺+苯二氮䓬、甲基苯丙胺+γ-羟基丁酸+苯二氮䓬。
  • 镇静定义为格拉斯哥昏迷评分(GCS)小于9。

红旗征与不能漏的情况

  • 甲基苯丙胺+γ-羟基丁酸组镇静(GCS<9)发生率为63%,显著高于单独甲基苯丙胺组的15%(P<0.0001)和甲基苯丙胺+苯二氮䓬组的27%(P<0.0001)。

研究设计与关键结果

  • 研究类型:前瞻性注册研究(Emerging Drugs Network of Australia Victoria),经伦理委员会批准,收集急诊非法药物就诊者的临床和血液分析数据。
  • 甲基苯丙胺血药浓度中位数:甲基苯丙胺+γ-羟基丁酸组(n=153)为0.20 mg/L(IQR 0.10-0.32 mg/L,95%CI 0.20-0.23 mg/L),甲基苯丙胺+γ-羟基丁酸+苯二氮䓬组(n=160)为0.20 mg/L(IQR 0.10-0.30 mg/L,95%CI 0.20-0.30 mg/L),均显著高于γ-羟基丁酸阴性组,包括单独甲基苯丙胺组(n=81,中位数0.10 mg/L,IQR 0.05-0.21 mg/L,95%CI 0.09-0.18 mg/L)和甲基苯丙胺+苯二氮䓬组(n=73,中位数0.10 mg/L,IQR 0.06-0.20 mg/L,95%CI 0.09-0.20 mg/L),P<0.0004。
  • 就诊心率中位数:甲基苯丙胺+γ-羟基丁酸组(n=153)为72次/分(IQR 63-86次/分,95%CI 70-78次/分),显著低于甲基苯丙胺+苯二氮䓬组(n=73,中位数84次/分,IQR 73-98次/分,95%CI 80-90次/分,P<0.0001)和单独甲基苯丙胺组(n=81,中位数110次/分,IQR 87-131次/分,95%CI 93-120次/分,P<0.0001)。
  • 就诊体温中位数:甲基苯丙胺+γ-羟基丁酸组为35.8°C(IQR 35.0-36.2°C,95%CI 35.6-35.9°C),显著低于甲基苯丙胺+苯二氮䓬组(中位数36.2°C,IQR 35.7-36.6°C,95%CI 36.0-36.4°C,P=0.017)和单独甲基苯丙胺组(中位数36.5°C,IQR 35.8-37.1°C,95%CI 36.2-36.7°C,P<0.0001)。
  • 就诊收缩压中位数:苯二氮䓬阳性组显著降低(P≤0.001),甲基苯丙胺+苯二氮䓬组为120 mmHg(IQR 109-132 mmHg,95%CI 116-124 mmHg),甲基苯丙胺+苯二氮䓬+γ-羟基丁酸组为124 mmHg(IQR 110-137 mmHg,95%CI 120-129 mmHg)。
  • 镇静(GCS<9)发生率:甲基苯丙胺+γ-羟基丁酸组为63%,显著高于甲基苯丙胺+苯二氮䓬组的27%(P<0.0001)和单独甲基苯丙胺组的15%(P<0.0001)。
  • 激越发生率:甲基苯丙胺+γ-羟基丁酸+苯二氮䓬组为17%(P<0.0001),甲基苯丙胺+γ-羟基丁酸组为34%(P=0.0004),均显著低于单独甲基苯丙胺组的58%。

证据类型、等级与局限

  • 证据类型:前瞻性注册研究(观察性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 急诊接诊经分析确认的甲基苯丙胺中毒患者时,若同时检出γ-羟基丁酸,就诊心率、体温和激越发生率较单独甲基苯丙胺暴露者显著降低,但镇静(GCS<9)发生率显著更高(63% vs 15%),需警惕气道与意识状态。
  • 作者认为,γ-氨基丁酸B受体激动剂可能有助于急性甲基苯丙胺中毒的管理(原文为假设性结论,尚需进一步研究)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Acute metamfetamine toxicity is characterized by stimulant effects and neuropsychiatric disturbance, which is attenuated by gamma-aminobutyric acid type A receptor agonists including benzodiazepines. We utilized clinical registry data to examine the effect of co-exposure to a gamma-aminobutyric acid type B receptor agonist (gamma-hydroxybutyrate) in illicit drug cases with analytically confirmed exposure to metamfetamine.

METHODS: The Emerging Drugs Network of Australia Victoria is an ethics board-approved prospective registry collecting clinical and analytical data (utilising blood samples) on emergency department illicit drug presentations. Comparison groups were defined by analytically confirmed exposure: lone metamfetamine, metamfetamine plus gamma-hydroxybutyrate, metamfetamine plus benzodiazepine, metamfetamine plus gamma-hydroxybutyrate plus benzodiazepine. Cases with co-exposure to other stimulants or sedatives were excluded.

RESULTS: Median metamfetamine blood concentrations were significantly greater in metamfetamine plus gamma-hydroxybutyrate (n = 153, median = 0.20 mg/L, interquartile range: 0.10-0.32 mg/L, 95 per cent confidence interval: 0.20-0.23 mg/L) and metamfetamine plus gamma-hydroxybutyrate plus benzodiazepine (n = 160, median = 0.20 mg/L, interquartile range: 0.10-0.30 mg/L, 95 per cent confidence interval: 0.20-0.30 mg/L) positive groups compared to gamma-hydroxybutyrate negative groups including metamfetamine (n = 81, median = 0.10 mg/L, interquartile range: 0.05-0.21 mg/L, 95 per cent confidence interval: 0.09-0.18 mg/L) and metamfetamine plus benzodiazepine (n = 73, median = 0.10 mg/L, interquartile range: 0.06-0.20 mg/L, 95 per cent confidence interval: 0.09-0.20 mg/L) groups (P < 0.0004). Presenting heart rate in metamfetamine plus gamma-hydroxybutyrate cases (n = 153, median = 72 beats per minute, interquartile range: 63-86 beats per minute, 95 per cent confidence interval: 70-78 beats per minute) was significantly lower than metamfetamine plus benzodiazepine cases (n = 73, median = 84 beats per minute, interquartile range: 73-98 beats per minute, 95 per cent confidence interval: 80-90 beats per minute, P < 0.0001), and lone metamfetamine cases (n = 81, median = 110 beats per minute, interquartile range: 87-131 beats per minute, 95 per cent confidence interval: 93-120 beats per minute, P < 0.0001). Presenting temperature in metamfetamine plus gamma-hydroxybutyrate cases (median = 35.8 °C, interquartile range: 35.0-36.2 °C, 95 per cent confidence interval 35.6-35.9 °C) was significantly lower than metamfetamine plus benzodiazepine cases (median 36.2 °C, interquartile range 35.7-36.6 °C, 95 per cent confidence interval, 36.0-36.4 °C, P = 0.017), and lone metamfetamine cases (median = 36.5 °C, interquartile range: 35.8-37.1 °C, 95 per cent confidence interval: 36.2-36.7 °C, P < 0.0001). Median presenting systolic blood pressure was significantly (P ≤ 0.001) lower in benzodiazepine positive groups (metamfetamine plus benzodiazepine median = 120 mmHg, interquartile range: 109-132 mmHg, 95 per cent confidence interval: 116-124 mmHg and metamfetamine plus benzodiazepine plus gamma-hydroxybutyrate median = 124 mmHg, interquartile range: 110-137 mmHg, 95 per cent confidence interval: 120-129 mmHg). Incidence of sedation (Glasgow Coma Scale less than 9) was significantly greater in metamfetamine plus gamma-hydroxybutyrate cases (63 per cent) compared to metamfetamine plus benzodiazepine cases (27 per cent, P < 0.0001) and lone metamfetamine cases (15 per cent, P < 0.0001). Incidence of agitation was significantly lower in metamfetamine plus gamma-hydroxybutyrate plus benzodiazepine cases (17 per cent, P < 0.0001) and metamfetamine plus gamma-hydroxybutyrate cases (34 per cent, P = 0.0004) compared to lone metamfetamine cases (58 per cent).

DISCUSSION: Differences in gamma-aminobutyric acid type A and B receptor physiology may offer a gamma-aminobutyric acid type B agonist-facilitated alternative pharmacodynamic mechanism able to attenuate metamfetamine stimulant and neuropsychiatric toxicity.

CONCLUSION: Metamfetamine intoxicated patients with analytically confirmed co-exposure to gamma-hydroxybutyrate had significantly reduced heart rate, body temperature and incidence of agitation compared to patients with lone metamfetamine exposure. Metamfetamine intoxicated patients with analytically confirmed co-exposure to a benzodiazepine had significantly reduced systolic blood pressure compared to patients with lone metamfetamine exposure. We hypothesize that gamma-aminobutyric acid type B receptor agonists may be beneficial in the management of acute metamfetamine toxicity.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Greene SL, Syrjanen R, Hodgson SE, et al. Co-exposure to gamma-hydroxybutyrate is associated with attenuated neuropsychiatric and stimulant effects of metamfetamine. Clin Toxicol (Phila). 2024. PMID: 38884342. doi:10.1080/15563650.2024.2353265

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。